Thursday, February 17, 2011 |
06:00:00 |
Registration |
|
06:15:00 |
Continental Breakfast | Meet and Consult Professors on Challenging Cases |
|
06:55:00 |
Welcome |
Andrew D. Zelenetz, MD, PhD
|
07:00:00 |
Lymphoma |
John P. Leonard
|
07:05:00 |
Introductions and Presession Survey |
|
07:15:00 |
Maintenance Therapy in Follicular Lymphoma |
Richard I. Fisher
|
07:30:00 |
Comment |
John P. Leonard
|
07:35:00 |
My Approach to Initial Management of Marginal Zone Lymphoma |
John P. Leonard
|
07:45:00 |
Comment |
Wyndham H. Wilson
|
07:50:00 |
DEBATE | Should we focus on overall survival or progression-free survival in follicular lymphoma? |
|
07:55:00 |
Overall Survival |
Andrew D. Zelenetz, MD, PhD
|
08:10:00 |
Progression-Free Survival |
Richard I. Fisher
|
08:25:00 |
Question-and-Answer Session |
|
08:35:00 |
Toward Optimal Initial Management of Mantle Cell Lymphoma |
Wyndham H. Wilson
|
08:50:00 |
Comment |
Laurie H. Sehn
|
08:55:00 |
My Approach to Initial Management of Diffuse Large B-Cell Lymphoma |
Laurie H. Sehn
|
09:10:00 |
Comment |
Joseph M. Connors
|
09:15:00 |
Controversies in Hodgkin Lymphoma |
Joseph M. Connors
|
09:30:00 |
Comment |
Steven Horwitz
|
09:35:00 |
Do New Therapies Change the Paradigm for Treatment of Peripheral T-Cell Lymphoma? |
Steven Horwitz
|
09:50:00 |
Comment |
John P. Leonard
|
09:55:00 |
Primary Central Nervous System Lymphoma |
Tracy T Batchelor
|
10:10:00 |
Question-and-Answer Session Postsession Survey |
|
10:15:00 |
Break |
|
10:25:00 |
Lymphoma Cases and Chronic Lymphocytic Leukemia |
John C. Byrd
|
10:30:00 |
Panel Discussion | Lymphoma Cases |
|
11:30:00 |
How I Manage Frontline Chronic Lymphocytic Leukemia |
John C. Byrd
|
11:45:00 |
Comment |
William G. Wierda
|
11:50:00 |
How I Manage Relapsed/Refractory Chronic Lymphocytic Leukemia |
William G. Wierda
|
12:05:00 |
Comment |
Jennifer R. Brown
|
12:10:00 |
Management of Autoimmune Issues in Chronic Lymphocytic Leukemia |
Jennifer R. Brown
|
12:25:00 |
Comment |
John C. Byrd
|
12:30:00 |
Question-and-Answer Session |
|
12:40:00 |
Adjourn |
|
13:55:00 |
Afternoon Workshop | Signaling Inhibitors |
Carlo M Croce
|
14:00:00 |
JAK2 Inhibitors |
Ross L. Levine
|
14:20:00 |
BCR | Downstream Therapeutic Targets |
Jennifer R. Brown
|
14:40:00 |
New Tyrosine Kinase and Signaling Inhibitors in CML |
Richard Van Etten
|
15:00:00 |
mTOR Inhibitors |
Sonali M. Smith
|
15:20:00 |
PI3K | Akt Pathway Inhibitors |
Jennifer R. Brown
|
15:40:00 |
CDK Inhibitors |
Noopur Raje
|
16:00:00 |
Adjourn |
|
18:30:00 |
Welcome Reception |
|
Friday, February 18, 2011 |
06:15:00 |
Continental Breakfast | Meet and Consult Professors on Challenging Cases |
|
06:55:00 |
Multiple Myeloma |
|
07:00:00 |
Welcome and Introductions |
Sundar Jagannath
|
07:05:00 |
Presession Survey |
|
07:15:00 |
Highlights in the Management of Elderly Patients With Newly Diagnosed Myeloma |
Sagar Lonial
|
07:30:00 |
Highlights in the Management of Transplantation-Eligible Patients With Newly Diagnosed Myeloma |
Donna Reece
|
07:40:00 |
DEBATE | Should all patients with myeloma receive maintenance therapy? |
|
07:45:00 |
PRO |
Sundar Jagannath
|
08:00:00 |
CON |
Keith Stewart
|
08:15:00 |
Question-and-Answer Session |
|
08:25:00 |
Highlights in the Management of Patients With Myeloma Relapsing After 1-3 Prior Therapies |
Jeffery Zonder
|
08:40:00 |
Promising New Drugs in Clinical Trials in Myeloma |
Keith Stewart
|
08:55:00 |
Update from the 6th International Workshop on the Biology and Therapy of Waldenstrom's Macroglobulinemia |
Steven P. Treon
|
09:15:00 |
Panel Discussion | Myeloma Cases |
|
10:05:00 |
Question-and-Answer Session Postsession Survey |
|
10:15:00 |
Break |
|
10:25:00 |
Myeloproliferative Neoplasms |
Martin S. Tallman
|
10:30:00 |
Keynote Lecture | Overview of Molecular Pathways in Myeloproliferative Diseases |
Ross L. Levine
|
11:00:00 |
How I Treat Newly Diagnosed Chronic Myeloid Leukemia |
Charles Schiffer
|
11:15:00 |
Comment |
Jerald P. Radich
|
11:20:00 |
How I Treat Myelofibrosis If No Clinical Trial Is Available |
Ruben A Mesa
|
11:35:00 |
Comment |
Elihu H. Estey
|
11:40:00 |
Question-and-Answer Session |
|
11:45:00 |
Perspectives on the Challenges of Clinical Trials |
Elihu H. Estey, Charles Schiffer, James C. Wade
|
12:45:00 |
Adjourn |
|
13:55:00 |
Afternoon Workshop | Epigenetics and Gene Expression |
Anas Younes
|
14:00:00 |
Epigenetics and the Biology of Hematologic Malignancies |
Anas Younes
|
14:20:00 |
HDAC Function and HDAC Inhibitors: Where Is the Selectivity? |
Jean-Pierre Issa
|
14:40:00 |
MicroRNA and the Biology of Hematologic Malignancies |
Carlo M Croce
|
15:00:00 |
HDAC Inhibitors in Phase III Clinical Trials |
Sundar Jagannath
|
15:20:00 |
Epigenetic Targeting of NF-κB in Lymphoid Malignancies |
John C. Byrd
|
15:40:00 |
Genomics and Its Clinical Relevancy |
Randy D. Gascoyne
|
16:00:00 |
Adjourn |
|
Saturday, February 19, 2011 |
06:15:00 |
Continental Breakfast | Meet and Consult Professors on Challenging Cases |
|
06:55:00 |
Acute Leukemias and Myelodysplastic Syndromes Moderator |
Charles Schiffer
|
07:00:00 |
Welcome and Introductions |
|
07:05:00 |
Presession Survey |
|
07:15:00 |
How I Manage Acute Myeloid Leukemia in Elderly Patients |
Harry Erba
|
07:35:00 |
Comment |
David Steensma
|
07:40:00 |
How I Manage Low-Risk Myelodysplastic Syndromes |
David Steensma
|
08:00:00 |
Comment |
Jean-Pierre Issa
|
08:05:00 |
Can Acute Promyelocytic Leukemia Be Managed Without Chemotherapy? |
Martin S. Tallman
|
08:25:00 |
Comment |
Charles Schiffer
|
08:30:00 |
Panel Discussion | Myeloid Malignancy Cases |
|
08:55:00 |
DEBATE | Molecular characterization of acute myeloid leukemia is of value in guiding therapy |
|
09:00:00 |
PRO |
Jerald P. Radich
|
09:15:00 |
CON |
Harry Erba
|
09:30:00 |
Question-and-Answer Session |
|
09:40:00 |
Aggressive Lymphoid Malignancies (Acute Lymphoblastic Leukemia, Lymphoblastic Leukemia, Burkitt Lymphoma) |
Daniel J. DeAngelo
|
10:00:00 |
Comment |
|
10:05:00 |
Question-and-Answer Session Postsession Survey |
|
10:15:00 |
Break |
|
10:25:00 |
Supportive Care in Hematologic Malignancies |
Andrew D. Zelenetz, MD, PhD
|
10:30:00 |
Cord Blood and Haploidentical Stem Cells | An Expanding Opportunity in Allogeneic Stem Cell Transplantation? |
|
10:55:00 |
Question-and-Answer Session |
|
11:05:00 |
Outlook for Management of Bone Disease in Multiple Myeloma |
Noopur Raje
|
11:30:00 |
Question-and-Answer Session |
|
11:40:00 |
Infectious Complications in Hematologic Malignancies |
James C. Wade
|
12:05:00 |
Question-and-Answer Session |
|
12:15:00 |
Management of Thrombocytopenia |
Charles Schiffer
|
12:40:00 |
Question-and-Answer Session |
|
12:45:00 |
Adjourn |
|
13:55:00 |
Afternoon Workshop | Monoclonal Antibodies |
Andrew D. Zelenetz, MD, PhD
|
14:00:00 |
Therapeutic Antibodies | A Decade of Design |
Natarajan Muthusamy
|
14:20:00 |
MoAbs in Hodgkin Lymphoma: Antibody-Drug Conjugates |
Joseph M. Connors
|
14:40:00 |
MoAbs in Multiple Myeloma |
Sagar Lonial
|
15:00:00 |
Non-Hodgkin Lymphoma: Conjugated and Nonconjugated MoAbs |
Anas Younes
|
15:20:00 |
The Nature of Future MoAbs in Leukemia |
William G. Wierda
|
15:40:00 |
Clinical Development of MoAbs | Lessons Learned |
|
16:00:00 |
Adjourn |
|
Sunday, February 20, 2011 |
06:30:00 |
Continental Breakfast |
|
06:55:00 |
Tumor Boards | Challenging Cases in Hematologic Malignancies and Attendee-Submitted Cases |
Andrew David Zelenetz
|
07:00:00 |
Acute Myeloid Leukemia | Myelodysplastic Syndromes |
Harry Erba, Daniel J. DeAngelo, Jean-Pierre Issa
|
07:30:00 |
Chronic Myeloid Leukemia | Myeloproliferative Neoplasms |
Ruben A Mesa, Elihu H. Estey, Jerald P. Radich, Ross L. Levine, Richard Van Etten
|
08:00:00 |
Chronic Lymphocytic Leukemia |
John C. Byrd, William G. Wierda, Andrew D. Zelenetz, MD, PhD
|
08:30:00 |
Lymphoma |
Randy D. Gascoyne, Joseph M. Connors, Steven Horwitz, Wyndham H. Wilson
|
09:00:00 |
Multiple Myeloma |
Sundar Jagannath, Sagar Lonial, Noopur Raje, Donna Reece, Keith Stewart, Jeffery Zonder
|
09:30:00 |
Adjourn |
|